Univ of South Florida Asthma Allergy and Immunology CRU
Welcome,         Profile    Billing    Logout  
 10 Trials 
27 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Potter, Jennifer S
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Recruiting
3
348
Europe, Canada, Japan, US, RoW
Remibrutinib, Placebo
Novartis Pharmaceuticals
Chronic Inducible Urticaria
03/26
12/28
SICA 2, NCT05322941: Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

Completed
2
333
US
AEF0117, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, Placebo oral capsule, Placebo
Aelis Farma, National Institute on Drug Abuse (NIDA)
Marijuana Abuse
04/24
07/24
NCT05432388 / 2021-006950-30: Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Recruiting
2
72
Europe, US
remibrutinib, (LOU064), placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Allergy, Peanut
03/25
03/25
KIOS-I, NCT05859035: Informational App Development for mHealth for Patient Self-Management of Opioid Use Disorder

Active, not recruiting
N/A
25
US
KIOS Informational App, KIOS-I
Biomedical Development Corporation, The University of Texas Health Science Center at San Antonio, National Institute on Drug Abuse (NIDA)
Opioid-Related Disorders
01/24
01/24
NCT06212557: KIOS Mobile App Evaluation

Recruiting
N/A
200
US
KIOS App, KIOS, KIOS App education, KIOS education, Treatment as usual, TAU
The University of Texas Health Science Center at San Antonio, National Institute on Drug Abuse (NIDA), Biomedical Development Corporation
Opioid Use Disorder
06/25
10/25
Greenhawt, Matthew
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
adored, NCT05003804: Allergic Disease Onset Prevention Study

Active, not recruiting
1/2
264
US, RoW
STMC-103H, Placebo
Siolta Therapeutics, Inc.
Atopic Dermatitis, Type 1 Hypersensitivity
11/24
10/25
Soteres, Daniel
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
3
73
Europe, Canada, Japan, US
Lanadelumab, DX-2930, SHP643, TAK-743
Shire, Takeda Development Center Americas, Inc.
Angioedema
05/23
05/23
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

Completed
3
610
US
Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP
Chiesi Farmaceutici S.p.A.
Asthma
06/24
06/24
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Recruiting
3
348
Europe, Canada, Japan, US, RoW
Remibrutinib, Placebo
Novartis Pharmaceuticals
Chronic Inducible Urticaria
03/26
12/28
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Active, not recruiting
3
698
Europe, Canada, Japan, US, RoW
LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label)
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
08/24
02/27
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
NCT04530123: Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Recruiting
2
90
Canada, US, RoW
Placebo, TAK-101, Gluten
Takeda
Celiac Disease
10/25
10/25
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed
2
153
Europe, Canada, US
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Takeda
Celiac Disease
11/24
11/24
NCT05432388 / 2021-006950-30: Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Recruiting
2
72
Europe, US
remibrutinib, (LOU064), placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Allergy, Peanut
03/25
03/25
HAErmony-1, NCT05121376 / 2021-003603-18: A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

Active, not recruiting
1/2
44
Europe, US, RoW
Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331, Dose 4 of BMN 331, Dose 5 of BMN 331, Dose 6 of BMN 331, Dose 7 of BMN 331
BioMarin Pharmaceutical, BioMarin Pharmaceutical Inc.
Hereditary Angioedema, HAE
11/28
11/28
Ponda, Punita
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Recruiting
1/2
192
Canada, US
Peanut SLIT-tablet, Placebo
ALK-Abelló A/S, Parexel
Peanut Allergy
01/26
02/26
adored, NCT05003804: Allergic Disease Onset Prevention Study

Active, not recruiting
1/2
264
US, RoW
STMC-103H, Placebo
Siolta Therapeutics, Inc.
Atopic Dermatitis, Type 1 Hypersensitivity
11/24
10/25
Leflein, Jeffrey
SWIFT-2, NCT04718103 / 2020-003611-10: A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Jul 2024 - Dec 2024 : H2'24 - Acceptance of regulatory submission in US (based on SWIFT-1 trial) for asthma
Completed
3
397
Europe, Canada, Japan, US, RoW
GSK3511294, Depemokimab, Placebo
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
04/24
04/24
PREPARED-1, NCT06339008: A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis

Recruiting
3
450
Europe, US, RoW
LY3650150, Placebo, Standard therapy for INCS
Eli Lilly and Company
Perennial Allergic Rhinitis (PAR)
10/25
02/27
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS)
Eli Lilly and Company, Dermira, Inc.
Atopic Dermatitis, Eczema
02/26
02/27
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Active, not recruiting
3
641
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
05/25
05/25
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Enrolling by invitation
3
310
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, Placebo
Eli Lilly and Company
Atopic Dermatitis, Eczema
06/26
06/26
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
Goldsobel, Alan B
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
NCT05392192: A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Completed
2
51
US
ADX-629, Placebo
Aldeyra Therapeutics, Inc.
Chronic Cough
04/23
04/23

Download Options